Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
144 Leser
Artikel bewerten:
(0)

Nexstim Oyj: Nexstim Signs Canadian Distribution Agreement for its SmartFocus TMS systems with Canadian Health Solutions CHS

Press release, Helsinki, 7 January 2019 at 1.00 pm EET

Nexstim Plc Signs Canadian Distribution Agreement for its SmartFocus TMS systems with Canadian Health Solutions CHS

Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), announces it has signed a distribution agreement with Canadian Health Solutions to bring its SmartFocus TMS system to the Canadian market. The system is expected to be launched in Canada in the next few months.

Dr. David Elias, CEO of Canadian Health Solutions CHS, commented: "An estimated 10 per cent of Canadians use health services for mood and anxiety disorders annually. According to Statistics Canada, 1,330,510Canadians over the age of 15 reported indicators for 'Major depression episode' in 2012*. Canadian Health Solutions ispleasedto be the distributor for Nexstim's NBT system, which is based on a unique transcranial magnetic stimulation (TMS) technology. Based upon our deep understanding and research into mental health issues, we believe Nexstim's system has great potential and could significantly benefit the large number of Canadians who are in need of improved treatment options for MDD."

Nexstim SmartFocusTM technology is differentiated by its sophisticated 3D navigation that uses its proprietary E-field algorithm to visualize the exact location, orientation and magnitude of the stimulation given to the brain to treat MDD.

Dr. David Elias continued: "Canadian Health Solutions has a successful record of development, implementation and delivery of tailored health solutions. Cost effectiveness and validated health outcomes are required for all our solutions. We are happy to partner with Nexstim in making TMS available to Canadians."

The distribution agreement covers both Nexstim's NBT system for the treatment of MDD as well as the Nexstim NBS system for presurgical mapping.

Martin Jamieson, Chairman and CEO of Nexstim Plc, said: "We are delighted to announce that we have signed an agreement with Canadian Health Solutions that has a long experience in implementing and delivering health solutions into the Canadian market. This agreement is an important step supporting our strategy to expand in North America, where we believe there is a significant commercial opportunity for our clearly differentiated NBT system for the treatment of MDD. "

*2012 Canadian Community Health Survey https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310046501

***

Further information is available on the website www.nexstim.com (http://www.nexstim.com/) or by contacting:

Nexstim
Martin Jamieson, Chairman and CEO
+44 771 516 3942
martin.jamieson@nexstim.com

Citigate Dewe Rogerson
David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
david.dible@citigatedewerogerson.com

About Nexstim Plc
Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBT) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.

Nexstim's NBT system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.

For more information please visit www.nexstim.com (http://www.nexstim.com) .

About Canadian Health Solutions CHS:www.canadianhealthsolutions.ca (http://www.canadianhealthsolutions.ca)

Nexstim Signs Distribution Agreement with Canadian Health Solutions (http://hugin.info/138152/R/2230556/876508.pdf)



This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2019 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.